StreetAlpha.app
Home › Stocks › CNTB

Connect Biopharma Holdings Ltd (CNTB)

$0.59
▼ −6.08%
LAST CLOSE · NOV 20

Connect Biopharma is a San Diego company developing rademikibart, an antibody in trials for asthma and COPD. It last closed at $0.59 on Nov 20, down 6.08% on the day. The next earnings report for CNTB is expected around Tue, Mar 30, 2027, after the close. For the quarter ended Sep 2026, CNTB reported EPS of -$0.26 on revenue of $736,000, with revenue up 4500.0% from a year ago. Over its last 8 reports the stock moved an average of 9.0% the session after earnings. Over the last 12 months CNTB insiders bought $4.4M of stock on the open market and sold $0, according to SEC Form 4 filings.

AI Auto Pilots
Is CNTB in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold CNTB.

Key Stats

Last 12 months
Results
Revenue
$3.7M
+382.0% vs a year ago
Net income
−$67.9M
−1849.7% margin
EPS (diluted)
−$1.14
Free cash flow
−$55.3M
−1504.2% margin
Valuation
Market cap
$38.0M
64.5M shares
P/E
–
No P/E while losing money
Price to sales
10.4
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$16.5M
At Sep 30
Shareholder equity
$12.1M
Shares outstanding
64.5M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $0$0FY2023FY2024: $26.0M$26.0MFY2024FY2025: $64K$64KFY2025

From CNTB's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.

Next report
Mar 30
Estimated date · After the close
Reported EPS
-$0.26
Quarter ended Sep 2026
Year ago EPS
-$0.31
Same quarter last year
Revenue
$736,000
+4500.0% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.16Dec '24Mar 2025: -$0.19Mar '25Jun 2025: -$0.23Jun '25Sep 2025: -$0.31Sep '25Dec 2025: -$0.27Dec '25Mar 2026: -$0.34Mar '26Jun 2026: -$0.27Jun '26Sep 2026: -$0.26Sep '26Latest -$0.26
Revenue by quarter
Dec 2024: $698,000Dec '24Mar 2025: $0Mar '25Jun 2025: $48,000Jun '25Sep 2025: $16,000Sep '25Dec 2025: $0Dec '25Mar 2026: $169,000Mar '26Jun 2026: $2.8MJun '26Sep 2026: $736,000Sep '26Latest $736,000
How CNTB moved after its last 8 reports
Average move the session after a report ±9.0%
Nov 16, 2026After the close−10.0%
Aug 12, 2026After the close+9.0%
May 12, 2026Time not announced+14.5%
Mar 31, 2026After the close+3.8%
Nov 12, 2025Time not announced+5.9%
Aug 13, 2025Time not announced+4.0%
May 15, 2025Time not announced−5.6%
Mar 31, 2025Time not announced−19.1%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on CNTBStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
Analyst calls from around the web
Last 90 days on CNTB: 0 upgrades, 0 downgrades, 0 initiations
Canaccord Genuity GroupReiterated
Nov 17  

StreetAlpha's curated list of analyst calls collected from around the web. It may be incomplete or inaccurate, is not a consensus and is not advice.

AI Starter and AI Pro
Full analyst coverage on CNTB
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on CNTB

Technical Analysis

CNTB · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 23% below its 20 day and 53% below its 50 day average. It is 249% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 31), near oversold. The nearest support is the Pivot S1 at $0.57, and the nearest resistance the Pivot at $0.61.

Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityNormal, 13.6%/day
Key levels
$3.8252 week high+547.5%
$2.06200 day average+249.2%
$1.58100 day average+167.8%
$0.9150 day average+54.2%
$0.87Swing high (Oct 30)+47.5%
$0.7320 day average+23.7%
$0.62Pivot R1+5.1%
$0.61Pivot+3.4%
$0.59Last close
$0.57Pivot S1−3.4%
$0.5552 week low−6.8%
$0.55Swing low (Nov 17)−6.8%
Indicators
RSI (14)31.05Weak, oversold below 30Neutral
MACD-0.10Above its signal lineBullish
Stochastic26.7Middle of its rangeNeutral
ADX (14)19.0No clear trend
Williams %R-84.9Oversold below −80, overbought above −20Oversold
CCI (20)-114.2Oversold below −100, overbought above 100Oversold
Rate of change−19.0%Change over 10 sessionsBearish
ATR (14)$0.08Typical daily range, 13.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CNTB

What happened before

See how CNTB did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow CNTB usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How CNTB has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for CNTBHow many large options trades hit CNTB, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

CNTB Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲40 buying vs 23 selling
  • ▲Held by funds +1.7 pts
  • ▲Funds holding +8
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding6557+14.0%
In funds' top 1000–
Held by funds23.3%21.6%+1.7 pts
New / increased17 / 2325 / 150.0%
Reduced / sold out14 / 99 / 10+21.1%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CNTB institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

CNTB Insider Trading

All filings →
Insider trading · 12 months
Insiders are buying
Bought$4.4M2 buys · 1 insider
Sold$00 sales · 0 insiders
2026-03 bought $4.0M2026-05 bought $372KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
May 29James HuangDirectorBuy150,000$2.48$372K
Mar 31James HuangDirectorBuy1,160,000$3.45$4.0M
Every insider buy and sale for CNTB over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See CNTB insider trades →

From SEC Form 4 filings by CNTB's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CNTB is in one of them and how their past CNTB trades turned out.

CNTB in the AI portfolios
Loading…

CNTB News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CNTB in an article yet. Here's the latest on the wider market.

CNTB in the news

About Connect Biopharma Holdings

Connect Biopharma is a biopharmaceutical company based in San Diego, California. It is developing rademikibart, an antibody designed to block a receptor involved in airway inflammation. The drug is in clinical trials for sudden worsening episodes of asthma and chronic obstructive pulmonary disease (COPD), which are lung conditions that make breathing difficult. The company's target market is patients with these diseases and the hospitals that treat them, although the drug is not yet approved for sale.

Headquarters
San Diego, CA